White Plains Hospital is a general medical and surgical, non-profit hospital located in White Plains, New York. In addition to providing general care to patients, it also operates a number of specialized programs, such as its cancer center. The hospital was founded in 1893 as a four-room hospital. As of 2012, White Plains Hospital treated 170,000 patients annually and is a member of the Montefiore Health System network. The total capacity of the hospital is 292 beds.
Care for individuals with laryngectomy (IWL) is complex, requiring access to specialized multidisciplinary services along the full care continuum. However, evidence supports that challenges are experienced by some IWL accessing supportive care, with current care systems not addressing patients' postoperative and long-term needs, contributing to poor outcomes and increased patient and caregiver burden. This study explored perceptions of IWL about overall health services and speech-language pathology (SLP) care to identify and prioritize opportunities for supportive care optimization. Concept mapping methodology was used to identify what IWL perceived were important to support their care. Through the multistep concept mapping process, qualitative and quantitative data were used to identify, then prioritize, critical elements of care that IWL feel should be optimized in the care pathway. Fourteen IWL from two health services generated 32 unique statements. Hierarchical cluster analysis revealed that statements fell within seven clusters: (1) comprehensive healthcare professional access and support; (2) psychological care and trust in healthcare; (3) supporting adjustment to life after surgery; (4) managing the treatment and recovery pathway; (5) communication restoration and peer-support; (6) inpatient care; and (7) no underlying theme. The Go-Zone map revealed 15 statements that were rated highest for importance, with the majority of these focusing on improving psychological care and adjustment postsurgery. IWL identified and prioritized actions to enhance services relating to preoperative education, psychological care, access to healthcare professionals, peer support, and financial supports. These findings can be used to inform an enhanced care pathway for IWL.
To better understand the gap in literature by comparing umbilical hernia repair techniques for < 2 cm umbilical hernias in patients with class I and class II obesity Methods: A retrospective review of data from the ACHQC was performed to include adult patients with a BMI of 30.0–39.9 kg/m2 who underwent elective UHR for a hernia defect of < 2 cm. Patients within each obesity underwent propensity score matching analysis for diabetes mellitus, hypertension, chronic obstructive pulmonary disorder, and smoking status. Outcomes of interest included: compare surgical site infection, surgical site occurrence, 30-day reoperation, recurrence, and re-admission. 1896 patients were included in the analysis after matching. There was no difference in 30-day recurrence, re-admission, or reoperation. There was a statistically greater number of SSO in the class II obesity group (4.6
Introduction: Heart failure (HF) is a major cause of morbidity and early hospital readmission in the United States. Remote patient monitoring (RPM) is increasingly used to support postdischarge care, but evidence remains mixed, and the prognostic value of day-to-day vital sign variability is unclear. This study evaluated whether physiologic variability and patient engagement during RPM were associated with 31-day HF readmission. Methods: A retrospective cohort study included 213 patients with HF enrolled in a postdischarge RPM program from June 2022 to April 2024. Patients recorded daily weight, blood pressure, and heart rate for up to 31 days after discharge. Vital sign variability metrics were generated by flagging days with threshold-crossing measurements and summarizing these fluctuations over the RPM monitoring period. Adjusted logistic regression models evaluated associations with 31-day HF readmission. Results: Pulse variability was significantly associated with 31-day readmission (OR 9.91, 95% CI 1.63-59.81, p = 0.011), while variability in weight and blood pressure showed no significant associations. Total vital sign variability also predicted readmission (OR 6.93, 95% CI 1.71-28.16, p = 0.007). Escalation outreach rate was strongly associated with readmission (OR 15.46, 95% CI 3.19-95.69, p = 0.001). Maximum brain natriuretic peptide values were higher among readmitted patients (p = 0.019). Conclusion: Variability in physiologic measures captured through remote monitoring, particularly pulse variability and overall fluctuation burden, may serve as clinically meaningful indicators of early decompensation. These findings highlight the potential value of dynamic RPM patterns in postdischarge risk assessment.
Objective:The aim of this qualitative research study was to understand the barriers to PA advancement in hospital governance as perceived by PAs in current hospital leadership roles.Methods:This qualitative study of hospital-based PA leaders used grounded theory methodology through one-on-one, informal, semistructured virtual interviews. Thematic content analysis was used to analyze and report patterns within interview data.Results:In examining the 14 completed interviews, thematic analysis yielded 4 major themes and multiple subthemes. The predominant themes were (I) professional barriers; (II) workplace barriers; (III) personal barriers; and (IV) tools for PA advancement.Conclusions:This study provides foundational data on perceived barriers to PA advancement in hospital governance from the perspectives of PA leaders. Gaining a deeper understanding of the challenges PAs encounter in pursuing hospital leadership roles can guide both the profession and health care organizations in implementing strategies to support PA leadership development and create more inclusive governance structures to meet the needs of a changing health care system.
TPS8668 Background: Immune checkpoint inhibitors (ICIs) reverse tumor-induced immune suppression and promote effective anti-tumor T-cell responses. Current standard of care (SOC) for Stage 4 NSCLC combining ICIs (e.g. pembrolizumab [pembro]) plus histology-appropriate chemotherapy (chemo) confers significant clinical benefit over chemo alone, yet many patients progress nonetheless, highlighting a large unmet medical need in this disease. EIK1001, a Toll-like receptor (TLR) 7/8 dual agonist, activates myeloid and plasmacytoid dendritic cells stimulating innate and adaptive immunity. In completed Phase 1 and ongoing Phase 2 studies, EIK1001 exhibits a manageable safety profile and encouraging anti-tumor activity both as monotherapy and in combination with ICIs. Methods: TeLuRide-008 (NCT#07365319) is a global, multicenter, randomized, double-blind, placebo-controlled, adaptive Phase 2/3 study of EIK1001 or placebo, in combination with pembro and histology-appropriate chemo in systemic-therapy-naïve pts with stage 4 NSCLC. In Phase 2, pts are randomized 1:1:1 to receive 1 of 2 doses of EIK1001 or placebo, + pembro and chemo (Part 1:Dose optimization; n~120), followed by additional enrollment with 1:1 randomization of new pts (n~160), at the EIK1001 selected dose or placebo (Part 2: Dose Expansion; n~280). If the study proceeds to Phase 3 (Part 3: Confirmatory), ongoing Phase 2 pts to continue treatment, and n~440 new pts will be randomized 1:1 to receive the selected dose of EIK1001 or placebo, + pembro and chemo (n = up to 750). Key eligibility criteria: pts ≥ 18 years of age, life expectancy ≥ 3 months, stage 4 NSCLC (NSQ or SQ), no actionable mutations requiring targeted therapy, ≥ 1 measurable lesion per RECIST v1.1, and no history of symptomatic pneumonitis. Primary objectives: evaluate efficacy and safety of 2 doses of EIK1001 + pembro and chemo for dose optimization and compare PFS (RECIST v1.1 by BICR) and OS between the selected EIK1001 dose and placebo, + pembro and chemo. Secondary objectives: safety and tolerability, ORR and DOR per RECIST v1.1 by BICR. Exploratory objectives: time to response, EIK1001 exposure-response relationships, and health-related quality of life. Clinical trial information: NCT#07365319 .
